Ziprasidone therapy for post-traumatic stress disorder

Zakaria Siddiqui, William A. Marcil, Subhash Bhatia, Sriram Ramaswamy, Frederick Petty

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We describe the cases of 2 men with chronic combat-induced post-traumatic stress disorder (PTSD) who benefited from therapy with ziprasidone. They did not have active psychotic symptoms. Both the patients had a history of inadequate response to previous trials of different psychotropic agents. Ziprasidone was considered because of its broad-spectrum actions on various neurotransmitters. To our knowledge, this is the first published report of the usefulness of ziprasidone in the pharmacotherapy of PTSD, although atypical antipsychotic agents (e.g., olanzapine, quetiapine and risperidone) have been reported to be beneficial in the treatment of this condition.

Original languageEnglish
Pages (from-to)430-431
Number of pages2
JournalJournal of Psychiatry and Neuroscience
Volume30
Issue number6
StatePublished - Nov 2005

Fingerprint

Post-Traumatic Stress Disorders
olanzapine
Risperidone
Antipsychotic Agents
Neurotransmitter Agents
Therapeutics
Drug Therapy
ziprasidone

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Ziprasidone therapy for post-traumatic stress disorder. / Siddiqui, Zakaria; Marcil, William A.; Bhatia, Subhash; Ramaswamy, Sriram; Petty, Frederick.

In: Journal of Psychiatry and Neuroscience, Vol. 30, No. 6, 11.2005, p. 430-431.

Research output: Contribution to journalArticle

Siddiqui, Zakaria ; Marcil, William A. ; Bhatia, Subhash ; Ramaswamy, Sriram ; Petty, Frederick. / Ziprasidone therapy for post-traumatic stress disorder. In: Journal of Psychiatry and Neuroscience. 2005 ; Vol. 30, No. 6. pp. 430-431.
@article{5c039f160c9c4befab5b5fe01afd4b6f,
title = "Ziprasidone therapy for post-traumatic stress disorder",
abstract = "We describe the cases of 2 men with chronic combat-induced post-traumatic stress disorder (PTSD) who benefited from therapy with ziprasidone. They did not have active psychotic symptoms. Both the patients had a history of inadequate response to previous trials of different psychotropic agents. Ziprasidone was considered because of its broad-spectrum actions on various neurotransmitters. To our knowledge, this is the first published report of the usefulness of ziprasidone in the pharmacotherapy of PTSD, although atypical antipsychotic agents (e.g., olanzapine, quetiapine and risperidone) have been reported to be beneficial in the treatment of this condition.",
author = "Zakaria Siddiqui and Marcil, {William A.} and Subhash Bhatia and Sriram Ramaswamy and Frederick Petty",
year = "2005",
month = "11",
language = "English",
volume = "30",
pages = "430--431",
journal = "Journal of Psychiatry and Neuroscience",
issn = "1180-4882",
publisher = "Canadian Medical Association",
number = "6",

}

TY - JOUR

T1 - Ziprasidone therapy for post-traumatic stress disorder

AU - Siddiqui, Zakaria

AU - Marcil, William A.

AU - Bhatia, Subhash

AU - Ramaswamy, Sriram

AU - Petty, Frederick

PY - 2005/11

Y1 - 2005/11

N2 - We describe the cases of 2 men with chronic combat-induced post-traumatic stress disorder (PTSD) who benefited from therapy with ziprasidone. They did not have active psychotic symptoms. Both the patients had a history of inadequate response to previous trials of different psychotropic agents. Ziprasidone was considered because of its broad-spectrum actions on various neurotransmitters. To our knowledge, this is the first published report of the usefulness of ziprasidone in the pharmacotherapy of PTSD, although atypical antipsychotic agents (e.g., olanzapine, quetiapine and risperidone) have been reported to be beneficial in the treatment of this condition.

AB - We describe the cases of 2 men with chronic combat-induced post-traumatic stress disorder (PTSD) who benefited from therapy with ziprasidone. They did not have active psychotic symptoms. Both the patients had a history of inadequate response to previous trials of different psychotropic agents. Ziprasidone was considered because of its broad-spectrum actions on various neurotransmitters. To our knowledge, this is the first published report of the usefulness of ziprasidone in the pharmacotherapy of PTSD, although atypical antipsychotic agents (e.g., olanzapine, quetiapine and risperidone) have been reported to be beneficial in the treatment of this condition.

UR - http://www.scopus.com/inward/record.url?scp=29144443515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29144443515&partnerID=8YFLogxK

M3 - Article

C2 - 16327877

AN - SCOPUS:29144443515

VL - 30

SP - 430

EP - 431

JO - Journal of Psychiatry and Neuroscience

JF - Journal of Psychiatry and Neuroscience

SN - 1180-4882

IS - 6

ER -